Vonda Reeves, MD
Gastroenterology · Flowood, MSNPI 1194713529
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Phathom Pharmaceuticals, Inc. at 55.9% of the total. Reporting peaked in 2024 at $27,304 and has fallen 68.1% since, to $8,698 in 2025. Among gastroenterology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 282 payments — averaging $139.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$22K
- Eli Lilly$13K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$817
- Laborie Medical Technologies Corp.$301
- plus $1K from 22 others
Across 11 payments — averaging $13,991 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Madrigal Pharmaceuticals$154K
What the payments were for
- Consulting fees$12,20031%
- Speaking & faculty fees$18,50047%
- Travel & lodging$2,8757%
- Food & beverage$5,72715%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 44 | $21,983 |
| Eli Lilly | 7 | $12,703 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 95 | $1,284 |
| AbbVie | 46 | $1,059 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $817 |
| Laborie Medical Technologies Corp. | 1 | $301 |
| Mauna Kea Technologies, Inc. | 1 | $140 |
| Medtronic | 1 | $117 |
| Regeneron Healthcare Solutions, Inc. | 2 | $112 |
| Nestle Healthcare Nutrition Inc. | 6 | $99 |
| Shire North American Group Inc | 1 | $74 |
| Ardelyx, Inc. | 4 | $68 |
| Intercept Pharmaceuticals, Inc. | 4 | $66 |
| Merck | 4 | $56 |
| Pfizer | 4 | $51 |
| Aries Pharmaceuticals, Inc. | 1 | $44 |
| Bristol Myers Squibb | 1 | $40 |
| Olympus America Inc. | 1 | $38 |
| Ironwood Pharmaceuticals, Inc | 2 | $36 |
| Pharmacosmos Therapeutics Inc. | 2 | $34 |
| Fujifilm Healthcare Americas Corporation | 1 | $32 |
| Ipsen Biopharmaceuticals, Inc | 2 | $30 |
| Johnson & Johnson | 1 | $25 |
| Redhill Biopharma Inc. | 1 | $23 |
| Sanofi | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Novo Nordisk | 1 | $15 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,302 in reported general payments places this provider in the 95th percentile of 127 gastroenterology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 54 | $69,632 |
| XifaxanRifaximin | 15 | $51,011 |
| TrulancePlecanatide | 41 | $35,800 |
| VoqueznaVonoprazan Fumarate | 12 | $16,983 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 95 | $15,389 |
| MotegrityPrucalopride Succinate | 20 | $13,007 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 181 | $4,747 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 35 | $4,699 |
| Mesalamine | 15 | $4,627 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 293 | $4,580 |
| Sucralfate | 47 | $3,830 |
| Famotidine | 242 | $3,423 |
| Omeprazole | 310 | $3,257 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 88 | $1,520 |
| Pantoprazole Sodium | 116 | $1,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $1,284 | $91,50991 claims |
| AbbVieLinzess | $1,059 | $69,63254 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $21,983 | $16,98312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $817 | $13,00720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 127 gastroenterology providers in Mississippi.
Other gastroenterology in Flowood
- Reed HoganFlowood$216K
- Reed HoganFlowood$35K
- Jane Claire WilliamsFlowood$16K
- Ronald KotfilaFlowood$10K
- Stewart BoydFlowood$4K
- Wassem JuakiemBiloxi$519K
- John PhillipsTupelo$150K
- Brian BorgJackson$68K
- Pegah Hosseini-CarrollJackson$62K
- Shou Jiang TangJackson$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.